Clinical trial to determine the effect of Famciclovir on Epstein-Barr virus activity as measured by EBV shedding in saliva of patients with Multiple Sclerosis. - Famciclovir in Multiple Sclerosis

Queen Mary University London0 个研究点目标入组 30 人开始时间: 2019年6月5日最近更新: 2024年9月9日

适应症

试验速览

暂无简介。

•People with MS aged over 18 who are taking Natalizumab (Tysabri) will be eligible for inclusion in this study. Participants must be able to provide informed consent to take part in this study.
•Are the trial subjects under 18? no
•Number of subjects for this age range: 0
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range 0

•People with MS who are taking interferon-beta preparations or teriflunomide will not be eligible for this study.
•People taking fingolimod, cladribine, alemtuzumab or ocrelizumab will be excluded.
•People with MS who are on additional immunomodulatory agents (either for MS treatment or other reasons) will not be eligible to take part in this study.
•Participants will be excluded if they have had a course of steroids within 3 months of study entry.
•People who are already taking antiviral or antiretroviral medication for any reason will be excluded from this study. People known to be allergic to penciclovir, acyclovir, valaciclovir or famciclovir will be excluded from the study.
•People taking probenecid will be excluded.
•People with significant renal (CKD 3 or 4) and/or liver impairment will not be eligible to take part in this study.
•People who are pregnant or breastfeeding will be excluded from this study, and those who are planning to become pregnant or unwilling to take precautions to prevent pregnancy will not be eligible to take part.
•People who are unable to provide informed consent for any reason will not be eligible to enter this study.

发起方